Treatment for Marginal Zone Lymphomas
Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The marginal zone is the area in the B-cell in which the mutation occurs in this type of cancer. MZLs represent 2-4% of all NHL cases.
Nodal marginal zone lymphomas involved the lymph nodes directly. Extranodal marginal zone lymphomas involve only organs outside of the lymphatic system, such as the thyroid, GI tract, or skin. These extranodal cancers are also called mucosa-associated lymphatic tissue lymphomas lymphomas, or MALT lymphomas.
Splenic marginal zone lymphomas are considered a class of their own.
Treatment
Treatment varies depending on the type of disease and stage. Radioimmunotherapy treatments such as the Zevalin regimen, though not yet approved for mainstream use, show promising results as MZL therapy.
Related Articles
Photo: Pexels
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
